ERBB2 and breast cancer: For example, Herceptin-conjugated liposomes carrying both doxorubicin and a fluorescent marker were utilized to track therapeutic response in HER2-positive breast cancer cells, providing insights into tumor regression and facilitating personalized treatment plans [84].